HIGHLIGHTS
- who: Ayman Abouzayed and collaborators from the Department of Medicinal Chemistry, Uppsala University, , Uppsala, SwedenTomsk Polytechnic University, Tomsk, Russia have published the paper: Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer, in the Journal: Pharmaceutics 2020, 12, 977 of /2020/
- what: By conjugation of the GRPR antagonist RM26 (D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 ) to an ABD (albumin-binding domain) the authors aimed to extend the blood circulation of peptides. The authors aimed to develop and perform preclinical . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.